CNBC's Jim Cramer called Sellas Life Sciences "a great spec" and gave the biotech stock "two thumbs up" during Mad Money's Lightning Round. ・Investor focus remains on Sellas' Phase 3 Regal trial ...

Other institutions, including Mariner and Ameritas Investment Partners, also increased exposure to the stock. ・Sellas said on Tuesday that its Phase 3 Regal AML study had reached 78 events as of May ...